Company Encyclopedia
View More
name
NRX Pharmaceuticals
NRXP.US
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co.
4.496 T
NRXP.USMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking150/182
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE170.76%A
    • Profit Margin-15727.27%E
    • Gross Margin59.92%A
  • Growth ScoreD
    • Revenue YoY0.00%C
    • Net Profit YoY-86.67%E
    • Total Assets YoY236.08%A
    • Net Assets YoY-36.83%E
  • Cash ScoreC
    • Cash Flow Margin-0.64%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreE
    • Gearing Ratio271.75%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NRX Pharmaceuticals posts Q3 loss and reports first revenue after Dura Medical acquisition

    NRX Pharmaceuticals reported a Q3 2025 operational loss of $4.0 million, up from $3.0 million in Q3 2024, due to increased R&D and administrative costs. The company recorded its first revenue of $0.2 million post-Dura Medical acquisition. Cash reserves are expected to support operations through Q2 2026. Future revenue growth is anticipated from further acquisitions and expansion of HOPE clinics in Florida.

    Reuters·
    US
    NRXP
    +4.93%
    Reuters·
    US
    NRXP
    +4.93%

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update | NRXP Stock News

    NRx Pharmaceuticals reported Q3 2025 financial results and provided a corporate update. Key highlights include the refiled ANDA for KETAFREE™, FDA Fast Track Designation for NRX-100, and new data supporting NRX-101. HOPE Therapeutics operates three revenue-generating facilities in Florida, with plans for more. NRx secured operating capital through July 2026 and expects increased revenue from clinical operations. The company is advancing NRX-100 and NRX-101 for treating suicidal depression and PTSD.

    StockTitan·
    US
    NRXP
    +4.93%
    StockTitan·
    US
    NRXP
    +4.93%

    NRx Pharmaceuticals (NASDAQ:NRXP) Issues Earnings Results

    NRx Pharmaceuticals (NASDAQ:NRXP) reported a quarterly loss of $0.18 per share, missing the consensus estimate of $0.08. The company had revenue of $0.24 million, below the expected $6.83 million. Shares fell 3.9% to $2.49. Institutional investors increased their holdings, and analysts have mixed ratings with a consensus price target of $34.75. NRx develops treatments for central nervous system disorders.

    Market Beat·
    US
    NRXP
    +4.93%
    Market Beat·
    US
    NRXP
    +4.93%

    NRX Pharmaceuticals Inc. to Release Third Quarter 2025 Financial Results

    NRX Pharmaceuticals Inc. will announce its third quarter 2025 financial results on November 17, 2025, prior to market opening. The results will be available on the company's website, and a conference call to discuss the results is scheduled for 8:30 am ET the same day, with a live webcast accessible online.

    Reuters·
    US
    NRXP
    +4.93%
    Reuters·
    US
    NRXP
    +4.93%

    HOPE Therapeutics Launches One-Day Depression Treatment in Florida

    HOPE Therapeutics, a subsidiary of NRX Pharmaceuticals, has launched the Ampa One Day (ONE-D) protocol for treating resistant depression at various locations in Florida. This initiative aims to provide patient care for individuals struggling with this condition. The information is generated by AI and should not be considered as financial or legal advice.

    Reuters·
    US
    NRXP
    +4.93%
    Reuters·
    US
    NRXP
    +4.93%